A comparative study of the iron-clearing properties of subcutaneously administered desferrioxamine and parabactin is presented. The evaluation was performed in both a noniron-overloaded bile-duct cannulated rat and an ironloaded Cebus monkey model. Parabactin was superior to desferrioxamine in both the rodent and the primate. Unlike ERHAPS IT IS NOT too surprising that a metal that
generally form tighter iron complexes, eg, enterobactin (iron formation constant [ICF] = lo" mol/L-')? than the former, eg, desferrioxamine (KF = lo3' mol/L-'). ' Eukaryotes generally use two different families of molecules in processing iron: storage proteins, eg, femtin, and transport proteins, eg, transfemn. The glycoprotein, transferrin, carries iron into cells for use in a variety of biologic events. 6 Once bound to its receptor on the cell surface, transferrin is internalized via coated vesicles7 and the ironprotein complex enters a nonlysosomal acidic vacuole within the cell, where the iron is released for storage as an iron-ferritin complex.
Iron use in primates is characterized by a highly efficient recycling process,*-" with no specific mechanism for eliminating this transition metal. Because it cannot be effectively cleared, the introduction of "excess leads to iron overload, hemochromatosis, and, ultimately, to peroxida- tive tissue damage. Despite the fact that hemochromatosis has received considerable attention from a variety of scientific discipline^,^^-'^ treatment remains essentially unchanged. Patients with primary hemochromatosis are still managed by phlebotomy, whereas those suffering from hemochromatosis secondary to blood transfusions must be maintained on chelation therapy. Subcutaneous infusion of desfemoxamine B, a hexacoordinate hydroxamate iron chelator produced by Streptomyces pilosus, is still regarded as the treatment of choice for handling transfusional iron ~verload.'~-'~ Although the drug's efficacy and longterm tolerability are well documented, it still suffers from a number of shortcomings associated with poor to moderate efficiency and marginal oral activity.
It has been shown in situ that desfemoxamine forms a 1 : 1 hexacoordinate octahedral complex with Fe(II1) with a formation constant' of 3 X lo3' mol/L-'. If one assumes that the same stoichiometry applies when desfemoxamine is administered to an animal, 10% or less of the calculated iron excretion is observed.24 This situation is further complicated by the fact that desfemoxamine has a very short halflife in the body and must therefore be administered by continuous infusion over long periods of time. Patient compliance thus becomes a significant c~nsideration.~' There are a number of possible solutions to this problem: the development of more efficient desferrioxamine analogues, the generation of an orally effective desfenioxamine, or simply the identification of structurally distinct, more efficient chelators. This report focuses on the third option. The first comprehensive study of the iron clearing properties of a catecholamide siderophore, parabactin, is presented.
MATERIALS AND METHODS

Materials.
Desfemoxamine B (DFO) was supplied by CibaGeigy Ltd (Basel, Switzerland) in the form of the methanesulfonate salt (trade name, Desferal). Parabactin was synthesized as previously described.26 Sprague-Dawley rats were purchased from Charles River (Wilmington, MA). Cebus apella monkeys were obtained from World Wide Primates (Miami, FL). All reagents and standard iron solutions were obtained from Aldrich Chemical Co (Milwaukee, WI). Nalgene metabolic cages, rat jackets, and fluid swivels were purchased from Harvard Bioscience (South Natick, MA). Intramedic polyethylene tubing was obtained from Fisher Scientific (Pittsburgh, PA). Atomic absorption measurements were made on a Perkin-Elmer model 5 100 PC (Norwalk, CT). Ultrapure salts were obtained from Johnson Matthey Electronics (Royston, UK). Imferon, an iron dextran solution, was obtained from Fisons (Bedford, MA). All hematologic screens" were performed by Allied Clinical Laboratories (Gainesville, FL). Cremophor RH-40 was obtained from BASF (Parsippany, NJ).
Male SpragueDawley rats averaging 400 g were housed in Nalgene plastic metabolic cages during the experimental period and were given free access to water. The animals were anesthetized using sodium pentobarbital (50 mg/kg) administered intraperitoneally (IP). The bile duct was cannulated using 22-gauge polyethylene tubing, about 1 cm from the duodenum. The cannula was inserted about 2 cm into the duct and, once bile flow was established, the cannula was tied snugly in place. A skin tunneling needle was inserted from the shoulder area around to the abdominal incision. The cannula was threaded through the needle until it emerged from the shoulder opening.
The cannula was then passed from the rat to the swivel inside a metal torque-transmitting tether, which was attached to a rodent jacket around the animal's chest. The cannula was directed from the rat to a Gilson micro fraction collector (Gilson Medical Electronics, Middleton, WI) by a fluid swivel mounted above the metabolic cage. This system allowed the animal to move freely in the cage while continuous bile samples were being collected. Bile samples were collected at 3-hour intervals for 48 hours. Urine samples were taken every 24 hours. Sample collection and handling are as previously described. 28 Primate iron loading. After intramuscular anesthesia with ketamine, an intravenous infusion was started in a leg vein. The iron dextran was added to approximately 90 mL of sterile normal saline and administered to the animals at a dose of 200 to 300 mg/kg. The iron solution was infused for 45 to 60 minutes. Two to three infusions, separated by 10 to 14 days, were necessary to load the monkeys to a level of 500 mg/kg of iron. This brought the serum transferrin iron saturation to 70% to 80%. The serum half-life of iron dextran in humans is 2.5 to 3 d a~s . 2~ We waited 20 half-lives (60 days) before using any of the animals in iron-clearing experiments.
Primate iron balance studies. Seven days before the administration of the drug, the animals were placed in metabolic cagesz4 and started on the low-iron liquid diet.*' Animals were maintained on the low-iron liquid diet for 7 days before drug administration. The animals were given food according to their body weight and their intake was very carefully monitored.
Three days before drug administration (day -2 to day 0), baseline iron intake and output values were measured. This same measurement was made for days + 1 through +3. The total amount of iron intake was compared with the total iron output.
Primate fecal and urine samples. Fecal and urine samples were collected at 24-hour intervals. The collections began 4 days before the administration of the test drug. Fecal samples were assayed for
Non-iron-overloaded bile-duct cannulated rat.
the presence of occult blood, weighed, and mixed with distilled deionized water and autoclaved for 30 minutes. The mixture was then freeze-dried, and a known portion of the powder was mixed with low-iron nitric acid and refluxed for 24 hours. Once any particulate matter in the digested samples was removed by centrifugation, iron concentrations were determined by flame atomic absorption (AA). Monkey urine samples were acidified and reconstituted to initial volume after sterilization, if necessary.
Drug preparation and administration. Both DFO and parabactin were administered subcutaneously (SC) to the rats in 40% Cremophor RH-40 at a dose of 150 pmol/kg. In the primates, DFO was administered SC in sterile water for injection at a dose of 150 pmol/ kg, while parabactin was administered SC in 40% Cremophor RH-40 at a dose of 150 pmol/kg.
Eficiency calculations. The efficiency of each ligand was calculated on the basis of a 1 : I ligand iron complex. In the monkeys, the numbers were generated by averaging the iron output for 4 days before the administration of the drug, subtracting these numbers from the 2-day iron clearance after the administration of the drug, and then dividing by the theoretical output. The efficiencies in the rodent model were calculated by subtracting the iron excretion of control animals from the iron excretion of the treated animals. This number was then divided by the theoretical output to obtain the efficiency.
RESULTS
Chelator-induced iron clearance in rodents.
The efficiency of parabactin was compared with that of DFO. Both drugs were administered subcutaneously at a dose of 150 pmol/kg. The efficiencies (Table 1) were calculated based on the assumption that both ligands form a 1/1 complex with iron under physiologic conditions. These calculations showed the efficiency of DFO to be 2.5% k 0.7% (range, 1.7% to 3.7%); approximately 74% of the ligand-promoted iron excretion was found in the bile and 26% was found in the urine. The drug-promoted iron excretion in the bile was complete in 2 1 hours (Fig 2) , whereas urinary excretion was complete in 24 hours. When comparing these results with the data obtained for parabactin, the catecholamide proved to be far superior, with an overall efficiency of 14.2% k 2.0% (range, 11.4% to 16.7%). Parabactin was approximately 5.8 times as effective as DFO (P < .OO l), and iron excretion was characterized by a much broader clearance curve than seen for DFO (Fig 2) . The maximum parabactin-induced biliary iron output occurred around 2 1 hours, but remained signifi- cant up to 36 hours. DFO-induced biliary iron clearance was essentially complete in 15 hours. As with DFO, what little parabactin-induced urinary iron excretion there was was complete in 24 hours. Furthermore, the ratio of biliary to urinary iron was even greater with parabactin than with DFO, ie, 90% in the bile and 10% in the urine. No untoward side effects were noted in the rodents.
Chelator-induced iron clearance in primates. The Cebus monkeys responded differently to the ligands than did the rats. The variability in ligand-induced iron clearance was higher in the monkeys than in the rats. However, with each animal serving as its own control, the effectiveness of the two chelators could be readily compared (Fig 3 and Table 2 ). The mode of DFO-induced iron excretion was different in primates, with 55% ofthe iron in the urine and 45% in the feces versus 26% and 74%, respectively, in the rodents. The efficiency of DFO increased from 2.5% k 0.7% in the rodents to 5.5% k 0.9% (range, 4.4% to 6.6%) in the primates. Unlike DFO, the efficiency of parabactin decreased on going from the rodents to the primates: 14.2% f 2% in the rodent to 9.7% k 1.4% (range, 7.6% to 11.3%) in the primates. Nevertheless, the efficiency was still 1.8 times that of DFO (P < .001). The mode of parabactin-induced iron excretion in the primate was essentially identical to that seen in the rodent, with 8% in the urine and 92% in the feces, versus 10% and 9076, respectively, in the rodents.
Treatment with DFO or parabactin significantly increases iron output over the baseline values in both the urine and the feces of the primates. DFO-promoted urinary iron excretion increased from a baseline of4 f 1 to 252 k 56 pg/kg ( P < .001), whereas fecal iron excretion increased from a baseline of 350 f 22 to 583 k 69 pg/kg (P < .001). In the case of parabactin administered subcutaneously at 150 pmol/kg, urinary iron excretion increased from a baseline of 4 f 1 to 65 f 42 pg/kg (P < .OOl), whereas fecal iron excretion increased from a baseline of 273 f 99 to 877 f 139 pg/kg ( P < .OO 1). Primate iron balance studies. It is critical to point out that in each experiment the level of iron in the food was measured with atomic absorption spectroscopy. The results, summarized in Table 3 , indicate that both DFO and parabactin can hold the monkeys in negative iron balance. The amount of iron absorbed by the untreated animals over a 3-day period is compared with the amount absorbed by treated animals over a 3-day period. Animals in a negative iron balance are putting out more iron than they are taking in. On the average, monkeys treated with 150 pmol/kg of DFO put out 0.24 mg/kg more iron than they took in ( P < .001), whereas animals treated with the same molar quantity of parabactin put out 0.58 mg/kg (P < .001).
Primate hematologic screens. For all untreated animals, complete blood counts (CBC) and kidney and liver profiles, except ferritin levels, were within the accepted normal range of the human values. Monkey femtin could not be measured using the commercially available human femtin antibody assay. Under the conditions of the experiments, there were no significant changes in the CBC or kidney and liver profiles.
We were unable to identify any toxic effects of parabactin in either the rodents or primates. The hematologic screens of the primates remained unchanged relative to untreated controls. However, it must be emphasized that this was a single dosage and that neither the rats nor the monkeys have been exposed to parabactin chronically.
Drug toxicity.
DISCUSSION
Unfortunately, the biologic evaluation of siderophores as iron-clearing agents has not paralleled the rate of their isolation and structural elucidation. Despite the enormous effort and expense invested, very few of the natural product chelators isolated have ever made it to animal models.
Although there are exceptions, the siderophores fall largely into two structural groups: the hydroxamates and the catecholamides. The most well known of the hydroxamates, desfemoxamine, is of course a very effective deferration agent. Its catecholamide counterpart, enterobactin, did not perform well at all in animals.30 However, this hexacoordinate catecholamide iron chelator, predicated on a macrocyclic serine backbone isolated from Escherichia coli, did receive a great deal of attention from the scientific community. A total synthesis was devised for the parent mole- Percentages are in parentheses.
cule3' as well as for several analogues and homologue^,^^"^ and a substantial effort was invested in a study of the molecule's iron binding proper tie^.^ Unfortunately, biologic experiments were not nearly as successful as the synthetic and the inorganic studies: the compound cleared little iron from the animals and was Interestingly, animals frequently died from septicemia. Although not proven, the thinking at the time was that the enterobactin-iron complex was a readily available iron source for microorganisms. Until this study, little has been reported on the efficiency of other natural product catecholamide chelators. In fact, the parabactin study is the most comprehensive investigation yet of a catecholamide chelator. This hexacoordinate ligand (Fig l) , isolated from Paracoccus denitrijicans, is predicated on a spermidine backbone.35 This means that, unlike the macrocyclic backbone of enterobactin, the parabactin framework is not subject to mild hydrolysis or to nonspecific serum esterases. Furthermore, it is the siderophore of a plant pathogen, and less likely to facilitate iron use by E coli.
The "prepackaged iron" enterobactin-induced septicemia in rodents is less of a threat.
Parabactin was clearly more effective than desfemoxa- The amount of iron absorbed by the untreated animals over a 3-day period is compared with the amount of iron absorbed by the treated animals over a 3-day period. Net iron balance = dietary iron intake -(urinary iron +fecal iron). Animals in a negative iron balance are putting out more iron than they are taking in. mine at iron clearance when both ligands were administered as an SC bolus, although other modes of delivery, ie, intravenous or SC infusions, might not show this difference. Nevertheless, in this study, parabactin was 5.8 times as efficient as DFO in the rodent model (P < .001) and was 1.8 times as efficient as DFO in the primate model (P < .001). Whereas the distribution of parabactin-promoted iron excretion in rodents and primates was essentially identical, with 90% of the iron in the bile/feces, this was not at all true with desfemoxamine. Both DFO and parabactin were effective at putting the primates in negative iron balance ( Table 3) . On the average, monkeys treated with 150 pmollkg of DFO put out 0.24 mg/kg more iron than they took in (P < .001), whereas animals treated with the same molar quantity of parabactin put out 0.58 mg/kg (P < .OO I). Unlike that in the rodent model, the protracted iron clearance seen with parabactin was not as obvious in the primates. To determine if this compound is a candidate for clinical evaluation, additional studies are needed to assess the effects of parabactin at the cellular level, as well as an evaluation of its potential toxicity when administered on a long-term basis. Notwithstanding, the data clearly suggest that catecholamide chelators merit further consideration as potential therapeutics in iron overload. More importantly, it seems critical that other natural product iron chelators should also be explored in appropriate animal models.
